Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Liquid Biopsies and Minimally-Invasive Diagnostics 2016

John Sninsky's Biography

John Sninsky, Chief Scientific Officer, CareDx

John Sninsky, Ph.D. is Chief Scientific Officer at CareDx, Inc., a California based molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value, non-invasive diagnostic surveillance solutions for transplant recipients. John brings experience in the discovery, development and application of diagnostic technologies, content and interpretive test solutions ranging from early stage biotechnology to international pharmaceutical organizations as well as in a range of small and enterprise diagnostic services and product settings.

John Sninsky Image

Cell-Free DNA: Potential Pan-Organ Marker for Organ Transplantation

Friday, 30 September 2016 at 11:00

Add to Calendar ▼2016-09-30 11:00:002016-09-30 12:00:00Europe/LondonCell-Free DNA: Potential Pan-Organ Marker for Organ TransplantationLiquid Biopsies and Minimally-Invasive Diagnostics 2016 in San Diego, California, USASan Diego, California,

Patients who have undergone organ transplants require frequent monitoring to evaluate the organ’s graft status and to modulate a complex regimen of immunosuppressive medications to address short and long term clinical needs. Sub-optimal dosing and the threat of allograft rejection must be balanced with excessive dosing and increased risks of infections and cancer. A significant unmet medical need exists for clinical diagnostic tools to permit surveillance management of transplant patients and improve the long-term outcomes of immunosuppressive therapy. Cell-free DNA (cfDNA) has been described as a biomarker for prenatal testing, cancer, and organ transplantation, each of which presents different clinical and technological challenges. cfDNA circulating in the plasma of transplant patients represents a mixture of residual nucleosomal-protected genomic regions released from dying cells of allograft (“transgenome”) and recipient cfDNA. The genomes of the organ donor and allograft recipient are distinguishable by next generation sequencing. Longitudinal samples from heart and kidney transplant patients showed significantly higher donor-derived cfDNA levels prior to biopsy-confirmed rejection which were reduced following adjustments to immunosuppressive therapy. The cfDNA compartment also harbors information about specific infectious diseases and somatic mutations associated with cancer development.  The role of Big Data in tracking organ transplantation outcomes will be discussed.

Add to Calendar ▼2016-09-29 00:00:002016-09-30 00:00:00Europe/LondonLiquid Biopsies and Minimally-Invasive Diagnostics 2016Liquid Biopsies and Minimally-Invasive Diagnostics 2016 in San Diego, California, USASan Diego, California,